Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– SMA Type 2 study to initiate in Q2 2017 –– Streamlines development of Type 2 clinical data set –– Conference call and webcast December 21, at 4:30 p.m. EST – CHICAGO, Dec. 21, 2016 (GLOBE...
-
– AVXS-101 demonstrated continued motor function improvement in ongoing study; majority of patients on proposed therapeutic dose achieved key developmental milestones – – Confirmed single-arm design...
-
CHICAGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
-
– Company provides update following receipt of FDA minutes from Type B meeting – – Conference call and webcast November 1 at 4:30 p.m. EDT – CHICAGO, Nov. 01, 2016 (GLOBE NEWSWIRE) --...
-
CHICAGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
-
-- Data, Including Developmental Milestones, as of September 15, 2016 as presented by Jerry Mendell, M.D. at the International Annual Congress of the World Muscle Society -- -- Webcast Today,...
-
CHICAGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock, 3,960,145 shares of...
-
CHICAGO, Sept. 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, 3,566,474 shares of its common stock in an...
-
-- Interim data through July 1 showed no “events” -- -- Continued motor function improvement with 25% of patients in the proposed therapeutic dose group in the normal range -- -- FDA requested...
-
CHICAGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...